nodes	percent_of_prediction	percent_of_DWPC	metapath
Adenosine—SLC28A3—nipple—skin cancer	0.0271	0.0828	CbGeAlD
Adenosine—ADORA1—nerve—skin cancer	0.0244	0.0746	CbGeAlD
Adenosine—DPP4—blood vessel—skin cancer	0.0193	0.0591	CbGeAlD
Adenosine—ADORA2B—nipple—skin cancer	0.0193	0.059	CbGeAlD
Adenosine—SLC28A3—mammalian vulva—skin cancer	0.0158	0.0483	CbGeAlD
Adenosine—ADK—nipple—skin cancer	0.0144	0.0441	CbGeAlD
Adenosine—ADA—Validated transcriptional targets of deltaNp63 isoforms—KRT5—skin cancer	0.014	0.0845	CbGpPWpGaD
Adenosine—ADA—Validated transcriptional targets of deltaNp63 isoforms—KRT14—skin cancer	0.013	0.0786	CbGpPWpGaD
Adenosine—ADA—connective tissue—skin cancer	0.0125	0.0383	CbGeAlD
Adenosine—DPP4—Peptide hormone metabolism—EXOC2—skin cancer	0.0114	0.069	CbGpPWpGaD
Adenosine—ADORA2B—mammalian vulva—skin cancer	0.0113	0.0344	CbGeAlD
Adenosine—Haemorrhage intracranial—Temozolomide—skin cancer	0.0112	0.0221	CcSEcCtD
Adenosine—ADA—mammalian vulva—skin cancer	0.0103	0.0315	CbGeAlD
Adenosine—DPP4—connective tissue—skin cancer	0.00991	0.0303	CbGeAlD
Adenosine—Tingling sensation—Imiquimod—skin cancer	0.00954	0.0188	CcSEcCtD
Adenosine—DPP4—epithelium—skin cancer	0.00941	0.0288	CbGeAlD
Adenosine—ADK—skin of body—skin cancer	0.00923	0.0282	CbGeAlD
Adenosine—ADA—lymphoid tissue—skin cancer	0.00915	0.028	CbGeAlD
Adenosine—ADA—female reproductive system—skin cancer	0.00882	0.027	CbGeAlD
Adenosine—ADK—mammalian vulva—skin cancer	0.00842	0.0257	CbGeAlD
Adenosine—ADORA2A—lymphoid tissue—skin cancer	0.00832	0.0255	CbGeAlD
Adenosine—DPP4—mammalian vulva—skin cancer	0.00816	0.025	CbGeAlD
Adenosine—ADORA2B—head—skin cancer	0.00806	0.0246	CbGeAlD
Adenosine—ADORA2A—female reproductive system—skin cancer	0.00803	0.0245	CbGeAlD
Adenosine—Sinus tachycardia—Docetaxel—skin cancer	0.00758	0.0149	CcSEcCtD
Adenosine—ADK—lymphoid tissue—skin cancer	0.00748	0.0229	CbGeAlD
Adenosine—ADA—head—skin cancer	0.00737	0.0225	CbGeAlD
Adenosine—DPP4—lymphoid tissue—skin cancer	0.00725	0.0222	CbGeAlD
Adenosine—ADK—female reproductive system—skin cancer	0.00721	0.022	CbGeAlD
Adenosine—DPP4—female reproductive system—skin cancer	0.00699	0.0214	CbGeAlD
Adenosine—ADORA1—female reproductive system—skin cancer	0.00693	0.0212	CbGeAlD
Adenosine—Atrial fibrillation—Vemurafenib—skin cancer	0.00689	0.0136	CcSEcCtD
Adenosine—ADORA2A—head—skin cancer	0.00671	0.0205	CbGeAlD
Adenosine—Dysgeusia—Vismodegib—skin cancer	0.00623	0.0123	CcSEcCtD
Adenosine—Back pain—Vismodegib—skin cancer	0.00615	0.0121	CcSEcCtD
Adenosine—Nasal congestion—Imiquimod—skin cancer	0.00611	0.012	CcSEcCtD
Adenosine—Scotoma—Temozolomide—skin cancer	0.00605	0.0119	CcSEcCtD
Adenosine—ADK—head—skin cancer	0.00602	0.0184	CbGeAlD
Adenosine—ADA—Validated transcriptional targets of TAp63 isoforms—SHH—skin cancer	0.00598	0.0362	CbGpPWpGaD
Adenosine—Atrial fibrillation—Imiquimod—skin cancer	0.00587	0.0116	CcSEcCtD
Adenosine—DPP4—head—skin cancer	0.00584	0.0179	CbGeAlD
Adenosine—ADORA1—head—skin cancer	0.00579	0.0177	CbGeAlD
Adenosine—Cardiac failure—Imiquimod—skin cancer	0.0057	0.0112	CcSEcCtD
Adenosine—Cerebrovascular accident—Imiquimod—skin cancer	0.00568	0.0112	CcSEcCtD
Adenosine—Tingling sensation—Fluorouracil—skin cancer	0.00527	0.0104	CcSEcCtD
Adenosine—Myocardial ischaemia—Fluorouracil—skin cancer	0.00527	0.0104	CcSEcCtD
Adenosine—ADA—lymph node—skin cancer	0.00516	0.0158	CbGeAlD
Adenosine—Numbness—Fluorouracil—skin cancer	0.00511	0.0101	CcSEcCtD
Adenosine—Sensory loss—Fluorouracil—skin cancer	0.00489	0.00962	CcSEcCtD
Adenosine—Musculoskeletal discomfort—Vismodegib—skin cancer	0.00473	0.00931	CcSEcCtD
Adenosine—Respiratory failure—Temozolomide—skin cancer	0.00468	0.00921	CcSEcCtD
Adenosine—Pain—Vismodegib—skin cancer	0.00444	0.00874	CcSEcCtD
Adenosine—Burning sensation—Docetaxel—skin cancer	0.0044	0.00866	CcSEcCtD
Adenosine—SLC28A3—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.00433	0.0262	CbGpPWpGaD
Adenosine—Acute coronary syndrome—Imiquimod—skin cancer	0.00423	0.00832	CcSEcCtD
Adenosine—ADK—lymph node—skin cancer	0.00422	0.0129	CbGeAlD
Adenosine—Myocardial infarction—Imiquimod—skin cancer	0.0042	0.00828	CcSEcCtD
Adenosine—Cardiac disorder—Vemurafenib—skin cancer	0.00419	0.00825	CcSEcCtD
Adenosine—DPP4—lymph node—skin cancer	0.00409	0.0125	CbGeAlD
Adenosine—Mediastinal disorder—Vemurafenib—skin cancer	0.00407	0.00801	CcSEcCtD
Adenosine—ADORA1—lymph node—skin cancer	0.00405	0.0124	CbGeAlD
Adenosine—Cerebrovascular accident—Bleomycin—skin cancer	0.00403	0.00794	CcSEcCtD
Adenosine—Scotoma—Docetaxel—skin cancer	0.00402	0.00792	CcSEcCtD
Adenosine—Dysgeusia—Vemurafenib—skin cancer	0.00385	0.00758	CcSEcCtD
Adenosine—Back pain—Vemurafenib—skin cancer	0.0038	0.00749	CcSEcCtD
Adenosine—Myocardial ischaemia—Docetaxel—skin cancer	0.0038	0.00748	CcSEcCtD
Adenosine—ADORA2B—G alpha (s) signalling events—MC1R—skin cancer	0.00378	0.0229	CbGpPWpGaD
Adenosine—Asthenia—Vismodegib—skin cancer	0.00372	0.00733	CcSEcCtD
Adenosine—Nasal congestion—Temozolomide—skin cancer	0.00366	0.00721	CcSEcCtD
Adenosine—ADA—Circadian rythm related genes—NKX2-1—skin cancer	0.00362	0.0219	CbGpPWpGaD
Adenosine—Tinnitus—Imiquimod—skin cancer	0.00359	0.00707	CcSEcCtD
Adenosine—Flushing—Imiquimod—skin cancer	0.00357	0.00704	CcSEcCtD
Adenosine—Mediastinal disorder—Imiquimod—skin cancer	0.00347	0.00683	CcSEcCtD
Adenosine—Chest discomfort—Docetaxel—skin cancer	0.00345	0.0068	CcSEcCtD
Adenosine—Arrhythmia—Imiquimod—skin cancer	0.00344	0.00677	CcSEcCtD
Adenosine—Cough—Vemurafenib—skin cancer	0.00343	0.00675	CcSEcCtD
Adenosine—Bronchospasm—Bleomycin—skin cancer	0.00336	0.00662	CcSEcCtD
Adenosine—Vomiting—Vismodegib—skin cancer	0.0033	0.0065	CcSEcCtD
Adenosine—Affect lability—Temozolomide—skin cancer	0.00328	0.00646	CcSEcCtD
Adenosine—Rash—Vismodegib—skin cancer	0.00327	0.00645	CcSEcCtD
Adenosine—Dermatitis—Vismodegib—skin cancer	0.00327	0.00644	CcSEcCtD
Adenosine—Back pain—Imiquimod—skin cancer	0.00324	0.00638	CcSEcCtD
Adenosine—Anaphylactic shock—Vemurafenib—skin cancer	0.00321	0.00632	CcSEcCtD
Adenosine—Mood swings—Temozolomide—skin cancer	0.00316	0.00622	CcSEcCtD
Adenosine—Cardiac failure—Fluorouracil—skin cancer	0.00315	0.0062	CcSEcCtD
Adenosine—Respiratory failure—Docetaxel—skin cancer	0.00311	0.00613	CcSEcCtD
Adenosine—Nausea—Vismodegib—skin cancer	0.00308	0.00607	CcSEcCtD
Adenosine—Agitation—Imiquimod—skin cancer	0.00308	0.00606	CcSEcCtD
Adenosine—Angioedema—Imiquimod—skin cancer	0.00306	0.00603	CcSEcCtD
Adenosine—Blood pressure increased—Docetaxel—skin cancer	0.00306	0.00602	CcSEcCtD
Adenosine—Injection site reaction—Docetaxel—skin cancer	0.00304	0.00598	CcSEcCtD
Adenosine—Syncope—Imiquimod—skin cancer	0.00301	0.00592	CcSEcCtD
Adenosine—Acute coronary syndrome—Bleomycin—skin cancer	0.003	0.00591	CcSEcCtD
Adenosine—Hypotension—Vemurafenib—skin cancer	0.003	0.0059	CcSEcCtD
Adenosine—Myocardial infarction—Bleomycin—skin cancer	0.00299	0.00588	CcSEcCtD
Adenosine—Palpitations—Imiquimod—skin cancer	0.00296	0.00583	CcSEcCtD
Adenosine—Loss of consciousness—Imiquimod—skin cancer	0.00295	0.0058	CcSEcCtD
Adenosine—Cough—Imiquimod—skin cancer	0.00292	0.00576	CcSEcCtD
Adenosine—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.00292	0.00575	CcSEcCtD
Adenosine—Cardiac arrest—Fluorouracil—skin cancer	0.00292	0.00575	CcSEcCtD
Adenosine—Convulsion—Imiquimod—skin cancer	0.0029	0.00572	CcSEcCtD
Adenosine—Hypertension—Imiquimod—skin cancer	0.00289	0.0057	CcSEcCtD
Adenosine—Chest pain—Imiquimod—skin cancer	0.00285	0.00562	CcSEcCtD
Adenosine—Anxiety—Imiquimod—skin cancer	0.00284	0.0056	CcSEcCtD
Adenosine—Discomfort—Imiquimod—skin cancer	0.00282	0.00555	CcSEcCtD
Adenosine—Dry mouth—Imiquimod—skin cancer	0.00279	0.00549	CcSEcCtD
Adenosine—Lightheadedness—Docetaxel—skin cancer	0.00273	0.00538	CcSEcCtD
Adenosine—Hypoaesthesia—Bleomycin—skin cancer	0.00272	0.00536	CcSEcCtD
Adenosine—Shock—Imiquimod—skin cancer	0.00269	0.0053	CcSEcCtD
Adenosine—ADORA1—Circadian rythm related genes—NKX2-1—skin cancer	0.00269	0.0163	CbGpPWpGaD
Adenosine—Tachycardia—Imiquimod—skin cancer	0.00267	0.00526	CcSEcCtD
Adenosine—Pollakiuria—Temozolomide—skin cancer	0.00266	0.00524	CcSEcCtD
Adenosine—Hyperhidrosis—Imiquimod—skin cancer	0.00264	0.00521	CcSEcCtD
Adenosine—Flushing—Bleomycin—skin cancer	0.00254	0.005	CcSEcCtD
Adenosine—Musculoskeletal discomfort—Imiquimod—skin cancer	0.00249	0.00491	CcSEcCtD
Adenosine—ADA—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—skin cancer	0.00249	0.0151	CbGpPWpGaD
Adenosine—ADORA2B—G alpha (s) signalling events—PTGER4—skin cancer	0.00248	0.015	CbGpPWpGaD
Adenosine—ADORA2A—G alpha (s) signalling events—MC1R—skin cancer	0.00248	0.015	CbGpPWpGaD
Adenosine—Paraesthesia—Imiquimod—skin cancer	0.00246	0.00484	CcSEcCtD
Adenosine—Dyspnoea—Imiquimod—skin cancer	0.00244	0.0048	CcSEcCtD
Adenosine—Somnolence—Imiquimod—skin cancer	0.00243	0.00479	CcSEcCtD
Adenosine—Flushing—Dactinomycin—skin cancer	0.00237	0.00466	CcSEcCtD
Adenosine—Hypersensitivity—Vemurafenib—skin cancer	0.00236	0.00465	CcSEcCtD
Adenosine—Atrial fibrillation—Docetaxel—skin cancer	0.00234	0.00461	CcSEcCtD
Adenosine—Pain—Imiquimod—skin cancer	0.00234	0.00461	CcSEcCtD
Adenosine—Acute coronary syndrome—Fluorouracil—skin cancer	0.00233	0.0046	CcSEcCtD
Adenosine—Myocardial infarction—Fluorouracil—skin cancer	0.00232	0.00457	CcSEcCtD
Adenosine—Asthenia—Vemurafenib—skin cancer	0.0023	0.00453	CcSEcCtD
Adenosine—Hypoaesthesia—Temozolomide—skin cancer	0.0023	0.00452	CcSEcCtD
Adenosine—Cardiac failure—Docetaxel—skin cancer	0.00227	0.00447	CcSEcCtD
Adenosine—ADA—Validated transcriptional targets of TAp63 isoforms—CDKN2A—skin cancer	0.00223	0.0135	CbGpPWpGaD
Adenosine—SLC28A3—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.0022	0.0133	CbGpPWpGaD
Adenosine—Urticaria—Imiquimod—skin cancer	0.00217	0.00428	CcSEcCtD
Adenosine—Tinnitus—Temozolomide—skin cancer	0.00215	0.00424	CcSEcCtD
Adenosine—DPP4—Metabolism of proteins—EXOC2—skin cancer	0.00215	0.013	CbGpPWpGaD
Adenosine—ADORA2A—GPCRs, Other—SMO—skin cancer	0.00215	0.013	CbGpPWpGaD
Adenosine—Cardiac disorder—Temozolomide—skin cancer	0.00214	0.00422	CcSEcCtD
Adenosine—Flushing—Temozolomide—skin cancer	0.00214	0.00422	CcSEcCtD
Adenosine—Dizziness—Vemurafenib—skin cancer	0.00212	0.00418	CcSEcCtD
Adenosine—Hypoaesthesia—Fluorouracil—skin cancer	0.00211	0.00416	CcSEcCtD
Adenosine—ADORA2B—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.0021	0.0127	CbGpPWpGaD
Adenosine—Mediastinal disorder—Temozolomide—skin cancer	0.00208	0.00409	CcSEcCtD
Adenosine—Cough—Bleomycin—skin cancer	0.00208	0.00409	CcSEcCtD
Adenosine—ADORA2A—Circadian rythm related genes—NKX2-1—skin cancer	0.00208	0.0126	CbGpPWpGaD
Adenosine—Vomiting—Vemurafenib—skin cancer	0.00204	0.00402	CcSEcCtD
Adenosine—Chest pain—Bleomycin—skin cancer	0.00203	0.00399	CcSEcCtD
Adenosine—Rash—Vemurafenib—skin cancer	0.00202	0.00398	CcSEcCtD
Adenosine—Dermatitis—Vemurafenib—skin cancer	0.00202	0.00398	CcSEcCtD
Adenosine—Hypersensitivity—Imiquimod—skin cancer	0.00202	0.00397	CcSEcCtD
Adenosine—Headache—Vemurafenib—skin cancer	0.00201	0.00396	CcSEcCtD
Adenosine—Discomfort—Bleomycin—skin cancer	0.002	0.00394	CcSEcCtD
Adenosine—Dysgeusia—Temozolomide—skin cancer	0.00197	0.00387	CcSEcCtD
Adenosine—Asthenia—Imiquimod—skin cancer	0.00196	0.00386	CcSEcCtD
Adenosine—Anaphylactic shock—Bleomycin—skin cancer	0.00194	0.00383	CcSEcCtD
Adenosine—Back pain—Temozolomide—skin cancer	0.00194	0.00383	CcSEcCtD
Adenosine—Nausea—Vemurafenib—skin cancer	0.0019	0.00375	CcSEcCtD
Adenosine—Arrhythmia—Fluorouracil—skin cancer	0.0019	0.00374	CcSEcCtD
Adenosine—ADORA2B—GPCR ligand binding—PTCH2—skin cancer	0.0019	0.0115	CbGpPWpGaD
Adenosine—Vision blurred—Temozolomide—skin cancer	0.00189	0.00373	CcSEcCtD
Adenosine—Bronchospasm—Docetaxel—skin cancer	0.00189	0.00371	CcSEcCtD
Adenosine—Tremor—Temozolomide—skin cancer	0.00188	0.00371	CcSEcCtD
Adenosine—Discomfort—Dactinomycin—skin cancer	0.00187	0.00368	CcSEcCtD
Adenosine—Agitation—Temozolomide—skin cancer	0.00185	0.00363	CcSEcCtD
Adenosine—Angioedema—Temozolomide—skin cancer	0.00184	0.00361	CcSEcCtD
Adenosine—Hypotension—Bleomycin—skin cancer	0.00182	0.00358	CcSEcCtD
Adenosine—Dizziness—Imiquimod—skin cancer	0.00181	0.00356	CcSEcCtD
Adenosine—ADORA2B—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.0018	0.0109	CbGpPWpGaD
Adenosine—ADORA1—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.00179	0.0108	CbGpPWpGaD
Adenosine—Palpitations—Temozolomide—skin cancer	0.00177	0.00349	CcSEcCtD
Adenosine—Musculoskeletal discomfort—Bleomycin—skin cancer	0.00177	0.00349	CcSEcCtD
Adenosine—Cough—Temozolomide—skin cancer	0.00175	0.00345	CcSEcCtD
Adenosine—Paraesthesia—Bleomycin—skin cancer	0.00174	0.00344	CcSEcCtD
Adenosine—Vision blurred—Fluorouracil—skin cancer	0.00174	0.00343	CcSEcCtD
Adenosine—Convulsion—Temozolomide—skin cancer	0.00174	0.00343	CcSEcCtD
Adenosine—Vomiting—Imiquimod—skin cancer	0.00174	0.00342	CcSEcCtD
Adenosine—Hypertension—Temozolomide—skin cancer	0.00173	0.00341	CcSEcCtD
Adenosine—Dyspnoea—Bleomycin—skin cancer	0.00173	0.00341	CcSEcCtD
Adenosine—Rash—Imiquimod—skin cancer	0.00172	0.0034	CcSEcCtD
Adenosine—Dermatitis—Imiquimod—skin cancer	0.00172	0.00339	CcSEcCtD
Adenosine—Headache—Imiquimod—skin cancer	0.00171	0.00337	CcSEcCtD
Adenosine—Anxiety—Temozolomide—skin cancer	0.0017	0.00336	CcSEcCtD
Adenosine—Discomfort—Temozolomide—skin cancer	0.00169	0.00333	CcSEcCtD
Adenosine—Acute coronary syndrome—Docetaxel—skin cancer	0.00168	0.00332	CcSEcCtD
Adenosine—Myocardial infarction—Docetaxel—skin cancer	0.00168	0.0033	CcSEcCtD
Adenosine—Dry mouth—Temozolomide—skin cancer	0.00167	0.00329	CcSEcCtD
Adenosine—Pain—Bleomycin—skin cancer	0.00166	0.00327	CcSEcCtD
Adenosine—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.00165	0.00325	CcSEcCtD
Adenosine—Anaphylactic shock—Temozolomide—skin cancer	0.00164	0.00323	CcSEcCtD
Adenosine—ADORA2A—G alpha (s) signalling events—PTGER4—skin cancer	0.00163	0.00987	CbGpPWpGaD
Adenosine—Nausea—Imiquimod—skin cancer	0.00162	0.0032	CcSEcCtD
Adenosine—ADORA1—GPCR ligand binding—PTCH2—skin cancer	0.00161	0.00977	CbGpPWpGaD
Adenosine—Convulsion—Fluorouracil—skin cancer	0.0016	0.00316	CcSEcCtD
Adenosine—Hyperhidrosis—Temozolomide—skin cancer	0.00158	0.00312	CcSEcCtD
Adenosine—Chest pain—Fluorouracil—skin cancer	0.00158	0.0031	CcSEcCtD
Adenosine—ADA—C-MYB transcription factor network—CDKN2A—skin cancer	0.00156	0.00947	CbGpPWpGaD
Adenosine—Discomfort—Fluorouracil—skin cancer	0.00156	0.00306	CcSEcCtD
Adenosine—Pain—Dactinomycin—skin cancer	0.00155	0.00305	CcSEcCtD
Adenosine—Urticaria—Bleomycin—skin cancer	0.00154	0.00304	CcSEcCtD
Adenosine—ADORA1—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.00153	0.00927	CbGpPWpGaD
Adenosine—Hypoaesthesia—Docetaxel—skin cancer	0.00153	0.00301	CcSEcCtD
Adenosine—Anaphylactic shock—Fluorouracil—skin cancer	0.00151	0.00297	CcSEcCtD
Adenosine—Musculoskeletal discomfort—Temozolomide—skin cancer	0.00149	0.00294	CcSEcCtD
Adenosine—Tachycardia—Fluorouracil—skin cancer	0.00147	0.0029	CcSEcCtD
Adenosine—Paraesthesia—Temozolomide—skin cancer	0.00147	0.0029	CcSEcCtD
Adenosine—ADA—C-MYB transcription factor network—PTGS2—skin cancer	0.00146	0.00886	CbGpPWpGaD
Adenosine—Dyspnoea—Temozolomide—skin cancer	0.00146	0.00288	CcSEcCtD
Adenosine—Somnolence—Temozolomide—skin cancer	0.00146	0.00287	CcSEcCtD
Adenosine—Hypersensitivity—Bleomycin—skin cancer	0.00143	0.00282	CcSEcCtD
Adenosine—Cardiac disorder—Docetaxel—skin cancer	0.00142	0.0028	CcSEcCtD
Adenosine—Flushing—Docetaxel—skin cancer	0.00142	0.0028	CcSEcCtD
Adenosine—Hypotension—Fluorouracil—skin cancer	0.00141	0.00278	CcSEcCtD
Adenosine—Pain—Temozolomide—skin cancer	0.0014	0.00276	CcSEcCtD
Adenosine—Asthenia—Bleomycin—skin cancer	0.00139	0.00275	CcSEcCtD
Adenosine—Mediastinal disorder—Docetaxel—skin cancer	0.00138	0.00272	CcSEcCtD
Adenosine—ADORA2B—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.00138	0.00837	CbGpPWpGaD
Adenosine—ADORA2A—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.00138	0.00835	CbGpPWpGaD
Adenosine—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.00138	0.00271	CcSEcCtD
Adenosine—ADORA2B—GPCR ligand binding—MC1R—skin cancer	0.00137	0.0083	CbGpPWpGaD
Adenosine—Arrhythmia—Docetaxel—skin cancer	0.00137	0.0027	CcSEcCtD
Adenosine—ADORA2B—C-MYB transcription factor network—CDKN2A—skin cancer	0.00137	0.00829	CbGpPWpGaD
Adenosine—Paraesthesia—Fluorouracil—skin cancer	0.00136	0.00267	CcSEcCtD
Adenosine—Dyspnoea—Fluorouracil—skin cancer	0.00135	0.00265	CcSEcCtD
Adenosine—Somnolence—Fluorouracil—skin cancer	0.00134	0.00264	CcSEcCtD
Adenosine—Hypersensitivity—Dactinomycin—skin cancer	0.00134	0.00263	CcSEcCtD
Adenosine—Dysgeusia—Docetaxel—skin cancer	0.00131	0.00258	CcSEcCtD
Adenosine—Urticaria—Temozolomide—skin cancer	0.0013	0.00256	CcSEcCtD
Adenosine—Asthenia—Dactinomycin—skin cancer	0.0013	0.00256	CcSEcCtD
Adenosine—Back pain—Docetaxel—skin cancer	0.00129	0.00254	CcSEcCtD
Adenosine—Pain—Fluorouracil—skin cancer	0.00129	0.00254	CcSEcCtD
Adenosine—ADORA2B—C-MYB transcription factor network—PTGS2—skin cancer	0.00128	0.00775	CbGpPWpGaD
Adenosine—ADORA2A—GPCR ligand binding—PTCH2—skin cancer	0.00125	0.00754	CbGpPWpGaD
Adenosine—Vomiting—Bleomycin—skin cancer	0.00124	0.00243	CcSEcCtD
Adenosine—Rash—Bleomycin—skin cancer	0.00123	0.00241	CcSEcCtD
Adenosine—Dermatitis—Bleomycin—skin cancer	0.00122	0.00241	CcSEcCtD
Adenosine—Hypersensitivity—Temozolomide—skin cancer	0.00121	0.00238	CcSEcCtD
Adenosine—Urticaria—Fluorouracil—skin cancer	0.0012	0.00236	CcSEcCtD
Adenosine—Syncope—Docetaxel—skin cancer	0.0012	0.00236	CcSEcCtD
Adenosine—ADORA2B—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.00118	0.00717	CbGpPWpGaD
Adenosine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.00118	0.00716	CbGpPWpGaD
Adenosine—Palpitations—Docetaxel—skin cancer	0.00118	0.00232	CcSEcCtD
Adenosine—ADORA2B—Signaling Pathways—RHOU—skin cancer	0.00118	0.00713	CbGpPWpGaD
Adenosine—Asthenia—Temozolomide—skin cancer	0.00118	0.00232	CcSEcCtD
Adenosine—ADORA1—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.00118	0.00712	CbGpPWpGaD
Adenosine—Loss of consciousness—Docetaxel—skin cancer	0.00117	0.00231	CcSEcCtD
Adenosine—ADORA1—GPCR ligand binding—MC1R—skin cancer	0.00117	0.00706	CbGpPWpGaD
Adenosine—Cough—Docetaxel—skin cancer	0.00117	0.00229	CcSEcCtD
Adenosine—Convulsion—Docetaxel—skin cancer	0.00116	0.00228	CcSEcCtD
Adenosine—Nausea—Bleomycin—skin cancer	0.00115	0.00227	CcSEcCtD
Adenosine—Hypertension—Docetaxel—skin cancer	0.00115	0.00227	CcSEcCtD
Adenosine—Vomiting—Dactinomycin—skin cancer	0.00115	0.00227	CcSEcCtD
Adenosine—Rash—Dactinomycin—skin cancer	0.00114	0.00225	CcSEcCtD
Adenosine—ADA—C-MYB transcription factor network—NRAS—skin cancer	0.00114	0.00689	CbGpPWpGaD
Adenosine—Chest pain—Docetaxel—skin cancer	0.00114	0.00224	CcSEcCtD
Adenosine—Hypersensitivity—Fluorouracil—skin cancer	0.00111	0.00219	CcSEcCtD
Adenosine—Dry mouth—Docetaxel—skin cancer	0.00111	0.00219	CcSEcCtD
Adenosine—Anaphylactic shock—Docetaxel—skin cancer	0.00109	0.00215	CcSEcCtD
Adenosine—ADK—Metabolism—PLIN2—skin cancer	0.00109	0.00658	CbGpPWpGaD
Adenosine—Dizziness—Temozolomide—skin cancer	0.00108	0.00213	CcSEcCtD
Adenosine—Nausea—Dactinomycin—skin cancer	0.00108	0.00212	CcSEcCtD
Adenosine—Shock—Docetaxel—skin cancer	0.00107	0.00211	CcSEcCtD
Adenosine—Tachycardia—Docetaxel—skin cancer	0.00106	0.00209	CcSEcCtD
Adenosine—Vomiting—Temozolomide—skin cancer	0.00104	0.00205	CcSEcCtD
Adenosine—Rash—Temozolomide—skin cancer	0.00103	0.00204	CcSEcCtD
Adenosine—Dermatitis—Temozolomide—skin cancer	0.00103	0.00203	CcSEcCtD
Adenosine—Headache—Temozolomide—skin cancer	0.00103	0.00202	CcSEcCtD
Adenosine—ADA—Circadian rythm related genes—CDK4—skin cancer	0.00102	0.00617	CbGpPWpGaD
Adenosine—Hypotension—Docetaxel—skin cancer	0.00102	0.00201	CcSEcCtD
Adenosine—ADORA1—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.00101	0.0061	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—RHOU—skin cancer	0.001	0.00606	CbGpPWpGaD
Adenosine—Dizziness—Fluorouracil—skin cancer	0.000999	0.00197	CcSEcCtD
Adenosine—ADORA2B—C-MYB transcription factor network—NRAS—skin cancer	0.000996	0.00603	CbGpPWpGaD
Adenosine—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000993	0.00196	CcSEcCtD
Adenosine—ADA—C-MYB transcription factor network—KRAS—skin cancer	0.00098	0.00593	CbGpPWpGaD
Adenosine—Paraesthesia—Docetaxel—skin cancer	0.000979	0.00193	CcSEcCtD
Adenosine—ADORA2B—GPCR ligand binding—SHH—skin cancer	0.000977	0.00592	CbGpPWpGaD
Adenosine—Nausea—Temozolomide—skin cancer	0.000974	0.00192	CcSEcCtD
Adenosine—ADORA2B—Signaling by GPCR—PTCH2—skin cancer	0.000973	0.00589	CbGpPWpGaD
Adenosine—Dyspnoea—Docetaxel—skin cancer	0.000972	0.00191	CcSEcCtD
Adenosine—Somnolence—Docetaxel—skin cancer	0.000969	0.00191	CcSEcCtD
Adenosine—Vomiting—Fluorouracil—skin cancer	0.00096	0.00189	CcSEcCtD
Adenosine—ADORA2A—NGF signalling via TRKA from the plasma membrane—FOXO4—skin cancer	0.00096	0.00581	CbGpPWpGaD
Adenosine—Rash—Fluorouracil—skin cancer	0.000952	0.00188	CcSEcCtD
Adenosine—Dermatitis—Fluorouracil—skin cancer	0.000951	0.00187	CcSEcCtD
Adenosine—Headache—Fluorouracil—skin cancer	0.000946	0.00186	CcSEcCtD
Adenosine—Pain—Docetaxel—skin cancer	0.000932	0.00184	CcSEcCtD
Adenosine—ADORA2B—GPCR ligand binding—SMO—skin cancer	0.000926	0.00561	CbGpPWpGaD
Adenosine—ADORA2B—GPCR ligand binding—PTCH1—skin cancer	0.000926	0.00561	CbGpPWpGaD
Adenosine—ADORA2A—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.000907	0.00549	CbGpPWpGaD
Adenosine—ADORA2B—GPCR ligand binding—PTGER4—skin cancer	0.000902	0.00546	CbGpPWpGaD
Adenosine—ADORA2A—GPCR ligand binding—MC1R—skin cancer	0.0009	0.00545	CbGpPWpGaD
Adenosine—Nausea—Fluorouracil—skin cancer	0.000897	0.00177	CcSEcCtD
Adenosine—ADK—Metabolism—CSPG4—skin cancer	0.000876	0.00531	CbGpPWpGaD
Adenosine—ADORA2B—C-MYB transcription factor network—KRAS—skin cancer	0.000857	0.00519	CbGpPWpGaD
Adenosine—ADA—C-MYB transcription factor network—HRAS—skin cancer	0.000833	0.00504	CbGpPWpGaD
Adenosine—ADORA1—GPCR ligand binding—SHH—skin cancer	0.000831	0.00503	CbGpPWpGaD
Adenosine—ADORA1—Signaling by GPCR—PTCH2—skin cancer	0.000828	0.00501	CbGpPWpGaD
Adenosine—Hypersensitivity—Docetaxel—skin cancer	0.000803	0.00158	CcSEcCtD
Adenosine—ADORA1—GPCR ligand binding—SMO—skin cancer	0.000788	0.00477	CbGpPWpGaD
Adenosine—ADORA1—GPCR ligand binding—PTCH1—skin cancer	0.000788	0.00477	CbGpPWpGaD
Adenosine—Asthenia—Docetaxel—skin cancer	0.000782	0.00154	CcSEcCtD
Adenosine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.000777	0.00471	CbGpPWpGaD
Adenosine—ADORA2B—GPCR downstream signaling—MC1R—skin cancer	0.000775	0.00469	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—RHOU—skin cancer	0.000773	0.00468	CbGpPWpGaD
Adenosine—ADORA1—GPCR ligand binding—PTGER4—skin cancer	0.000767	0.00464	CbGpPWpGaD
Adenosine—ADORA1—Circadian rythm related genes—CDK4—skin cancer	0.000758	0.00459	CbGpPWpGaD
Adenosine—ADA—Metabolism—PLIN2—skin cancer	0.000739	0.00447	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by NGF—FOXO4—skin cancer	0.000738	0.00447	CbGpPWpGaD
Adenosine—ADORA2B—C-MYB transcription factor network—HRAS—skin cancer	0.000729	0.00441	CbGpPWpGaD
Adenosine—Dizziness—Docetaxel—skin cancer	0.000721	0.00142	CcSEcCtD
Adenosine—ADORA2B—Signaling by GPCR—MC1R—skin cancer	0.000704	0.00426	CbGpPWpGaD
Adenosine—Vomiting—Docetaxel—skin cancer	0.000693	0.00136	CcSEcCtD
Adenosine—Rash—Docetaxel—skin cancer	0.000687	0.00135	CcSEcCtD
Adenosine—Dermatitis—Docetaxel—skin cancer	0.000687	0.00135	CcSEcCtD
Adenosine—Headache—Docetaxel—skin cancer	0.000683	0.00134	CcSEcCtD
Adenosine—ADORA1—GPCR downstream signaling—MC1R—skin cancer	0.000659	0.00399	CbGpPWpGaD
Adenosine—Nausea—Docetaxel—skin cancer	0.000647	0.00127	CcSEcCtD
Adenosine—ADORA2A—GPCR ligand binding—SHH—skin cancer	0.000641	0.00388	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by GPCR—PTCH2—skin cancer	0.000639	0.00387	CbGpPWpGaD
Adenosine—ADORA2A—GPCR ligand binding—PTCH1—skin cancer	0.000608	0.00368	CbGpPWpGaD
Adenosine—ADORA2A—GPCR ligand binding—SMO—skin cancer	0.000608	0.00368	CbGpPWpGaD
Adenosine—ADORA1—Signaling by GPCR—MC1R—skin cancer	0.000598	0.00362	CbGpPWpGaD
Adenosine—ADK—Metabolism—ENO2—skin cancer	0.000596	0.00361	CbGpPWpGaD
Adenosine—ADA—Metabolism—CSPG4—skin cancer	0.000596	0.00361	CbGpPWpGaD
Adenosine—ADORA2A—GPCR ligand binding—PTGER4—skin cancer	0.000592	0.00358	CbGpPWpGaD
Adenosine—ADORA2A—Circadian rythm related genes—CDK4—skin cancer	0.000585	0.00354	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—PTCH2—skin cancer	0.000575	0.00348	CbGpPWpGaD
Adenosine—ADORA2B—GPCR downstream signaling—PTGER4—skin cancer	0.00051	0.00309	CbGpPWpGaD
Adenosine—ADORA2A—GPCR downstream signaling—MC1R—skin cancer	0.000509	0.00308	CbGpPWpGaD
Adenosine—ADORA2A—NGF signalling via TRKA from the plasma membrane—BRAF—skin cancer	0.000508	0.00307	CbGpPWpGaD
Adenosine—ADORA2B—Signaling by GPCR—SHH—skin cancer	0.000501	0.00304	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—PTCH2—skin cancer	0.000489	0.00296	CbGpPWpGaD
Adenosine—ADORA2B—Signaling by GPCR—SMO—skin cancer	0.000475	0.00288	CbGpPWpGaD
Adenosine—ADORA2B—Signaling by GPCR—PTCH1—skin cancer	0.000475	0.00288	CbGpPWpGaD
Adenosine—ADORA2B—Signaling by GPCR—PTGER4—skin cancer	0.000463	0.0028	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by GPCR—MC1R—skin cancer	0.000462	0.0028	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—GLI2—skin cancer	0.000436	0.00264	CbGpPWpGaD
Adenosine—ADA—Circadian rythm related genes—TP53—skin cancer	0.000433	0.00262	CbGpPWpGaD
Adenosine—ADORA1—GPCR downstream signaling—PTGER4—skin cancer	0.000433	0.00262	CbGpPWpGaD
Adenosine—ADORA1—Signaling by GPCR—SHH—skin cancer	0.000426	0.00258	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—MC1R—skin cancer	0.000416	0.00252	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—GLI1—skin cancer	0.00041	0.00248	CbGpPWpGaD
Adenosine—ADA—Metabolism—ENO2—skin cancer	0.000405	0.00245	CbGpPWpGaD
Adenosine—ADORA1—Signaling by GPCR—SMO—skin cancer	0.000404	0.00245	CbGpPWpGaD
Adenosine—ADORA1—Signaling by GPCR—PTCH1—skin cancer	0.000404	0.00245	CbGpPWpGaD
Adenosine—ADA—Circadian rythm related genes—IL6—skin cancer	0.000397	0.0024	CbGpPWpGaD
Adenosine—ADORA1—Signaling by GPCR—PTGER4—skin cancer	0.000393	0.00238	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by NGF—BRAF—skin cancer	0.00039	0.00236	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—SUFU—skin cancer	0.000388	0.00235	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—PTCH2—skin cancer	0.000377	0.00229	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—GLI2—skin cancer	0.00037	0.00224	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—MC1R—skin cancer	0.000353	0.00214	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—GLI1—skin cancer	0.000348	0.00211	CbGpPWpGaD
Adenosine—ADK—Metabolism—ERCC2—skin cancer	0.000346	0.0021	CbGpPWpGaD
Adenosine—ADORA2A—GPCR downstream signaling—PTGER4—skin cancer	0.000335	0.00203	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—SUFU—skin cancer	0.00033	0.002	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by GPCR—SHH—skin cancer	0.000329	0.00199	CbGpPWpGaD
Adenosine—ADORA1—Circadian rythm related genes—TP53—skin cancer	0.000322	0.00195	CbGpPWpGaD
Adenosine—ADORA2A—NGF signalling via TRKA from the plasma membrane—NRAS—skin cancer	0.000319	0.00193	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by GPCR—SMO—skin cancer	0.000312	0.00189	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by GPCR—PTCH1—skin cancer	0.000312	0.00189	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by GPCR—PTGER4—skin cancer	0.000304	0.00184	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—SHH—skin cancer	0.000296	0.00179	CbGpPWpGaD
Adenosine—ADORA1—Circadian rythm related genes—IL6—skin cancer	0.000295	0.00179	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—RASA1—skin cancer	0.000294	0.00178	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—GLI2—skin cancer	0.000286	0.00173	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—SMO—skin cancer	0.000281	0.0017	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—PTCH1—skin cancer	0.000281	0.0017	CbGpPWpGaD
Adenosine—ADORA2A—NGF signalling via TRKA from the plasma membrane—KRAS—skin cancer	0.000275	0.00166	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—PTGER4—skin cancer	0.000273	0.00166	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—MC1R—skin cancer	0.000273	0.00165	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—GLI1—skin cancer	0.000269	0.00163	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—SUFU—skin cancer	0.000255	0.00154	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—SHH—skin cancer	0.000252	0.00153	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—RASA1—skin cancer	0.00025	0.00152	CbGpPWpGaD
Adenosine—ADORA2A—Circadian rythm related genes—TP53—skin cancer	0.000249	0.00151	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by NGF—NRAS—skin cancer	0.000245	0.00149	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—FOXO4—skin cancer	0.000241	0.00146	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—PTCH1—skin cancer	0.000239	0.00145	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—SMO—skin cancer	0.000239	0.00145	CbGpPWpGaD
Adenosine—ADA—Metabolism—ERCC2—skin cancer	0.000235	0.00142	CbGpPWpGaD
Adenosine—ADORA2A—NGF signalling via TRKA from the plasma membrane—HRAS—skin cancer	0.000233	0.00141	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—PTGER4—skin cancer	0.000232	0.00141	CbGpPWpGaD
Adenosine—ADORA2A—Circadian rythm related genes—IL6—skin cancer	0.000228	0.00138	CbGpPWpGaD
Adenosine—ADORA2A—NGF signalling via TRKA from the plasma membrane—IL6—skin cancer	0.000223	0.00135	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by NGF—KRAS—skin cancer	0.000211	0.00128	CbGpPWpGaD
Adenosine—ADK—Metabolism—PTGS2—skin cancer	0.000207	0.00126	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—FOXO4—skin cancer	0.000205	0.00124	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—SHH—skin cancer	0.000194	0.00118	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—RASA1—skin cancer	0.000193	0.00117	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—SMO—skin cancer	0.000184	0.00112	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—PTCH1—skin cancer	0.000184	0.00112	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by NGF—HRAS—skin cancer	0.000179	0.00109	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—PTGER4—skin cancer	0.000179	0.00109	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by NGF—IL6—skin cancer	0.000172	0.00104	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—TERT—skin cancer	0.000161	0.000977	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—FOXO4—skin cancer	0.000159	0.00096	CbGpPWpGaD
Adenosine—ADA—Metabolism—PTGS2—skin cancer	0.000141	0.000854	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—TERT—skin cancer	0.000137	0.00083	CbGpPWpGaD
Adenosine—ADORA2B—Signaling by GPCR—NRAS—skin cancer	0.000136	0.000823	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—BRAF—skin cancer	0.000128	0.000773	CbGpPWpGaD
Adenosine—ADORA2B—Signaling by GPCR—KRAS—skin cancer	0.000117	0.000708	CbGpPWpGaD
Adenosine—ADORA1—Signaling by GPCR—NRAS—skin cancer	0.000116	0.0007	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—BRAF—skin cancer	0.000109	0.000658	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—TERT—skin cancer	0.000106	0.000641	CbGpPWpGaD
Adenosine—ADORA1—Signaling by GPCR—KRAS—skin cancer	9.94e-05	0.000602	CbGpPWpGaD
Adenosine—ADORA2B—Signaling by GPCR—HRAS—skin cancer	9.94e-05	0.000602	CbGpPWpGaD
Adenosine—ADORA2B—Signaling by GPCR—IL6—skin cancer	9.51e-05	0.000576	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by GPCR—NRAS—skin cancer	8.92e-05	0.00054	CbGpPWpGaD
Adenosine—ADORA1—Signaling by GPCR—HRAS—skin cancer	8.45e-05	0.000512	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—BRAF—skin cancer	8.38e-05	0.000508	CbGpPWpGaD
Adenosine—ADORA1—Signaling by GPCR—IL6—skin cancer	8.09e-05	0.00049	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—NRAS—skin cancer	8.03e-05	0.000486	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by GPCR—KRAS—skin cancer	7.68e-05	0.000465	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—KRAS—skin cancer	6.91e-05	0.000418	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—NRAS—skin cancer	6.82e-05	0.000413	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by GPCR—HRAS—skin cancer	6.53e-05	0.000395	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by GPCR—IL6—skin cancer	6.25e-05	0.000378	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—TP53—skin cancer	6.14e-05	0.000372	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—KRAS—skin cancer	5.87e-05	0.000356	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—HRAS—skin cancer	5.87e-05	0.000356	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—IL6—skin cancer	5.62e-05	0.00034	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—NRAS—skin cancer	5.27e-05	0.000319	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—TP53—skin cancer	5.22e-05	0.000316	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—HRAS—skin cancer	4.99e-05	0.000302	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—IL6—skin cancer	4.78e-05	0.000289	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—KRAS—skin cancer	4.54e-05	0.000275	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—TP53—skin cancer	4.03e-05	0.000244	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—HRAS—skin cancer	3.85e-05	0.000233	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—IL6—skin cancer	3.69e-05	0.000223	CbGpPWpGaD
